Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ)
CNY 4.26
(-3.4%)
CNY 4.26
(-3.4%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 656.89 Million | 840.65 Million | 811.18 Million | 877.91 Million | 1.34 Billion | 2.58 Billion |
| Cost of Revenue | 197.92 Million | 199.66 Million | 307.97 Million | 318.41 Million | 537.06 Million | 629.38 Million |
| Gross Profit | 458.96 Million | 640.98 Million | 503.2 Million | 559.5 Million | 806.96 Million | 1.95 Billion |
| Operating Expenses | 548.76 Million | 624.13 Million | 761.42 Million | 1.07 Billion | 1.36 Billion | 1.6 Billion |
| Selling, General and Administrative Expenses | 439.61 Million | 481.17 Million | 593.36 Million | 678.86 Million | 1 Billion | 1.26 Billion |
| Research and Development Expenses | 52.5 Million | 35.64 Million | 38.63 Million | 252.87 Million | 191.29 Million | 156.35 Million |
| Other Expenses | 22.09 Million | 107.31 Million | 129.42 Million | 142.23 Million | 168.54 Million | -11.17 Million |
| Cost and Expenses | 793.97 Million | 823.8 Million | 1.06 Billion | 1.39 Billion | 1.89 Billion | 2.23 Billion |
| Operating Income | -104.37 Million | 14.46 Million | -21.47 Million | -514.47 Million | -555.28 Million | 254.93 Million |
| Interest Expense | 39.93 Million | 52.4 Million | 86.09 Million | 106.15 Million | 105.02 Million | 84.62 Million |
| Income Tax Expense | 32.83 Million | 10.33 Million | 46.19 Million | 3.38 Million | 1.78 Million | 45.22 Million |
| Earnings before Tax | -173.66 Million | -90.55 Million | -155.44 Million | -1.15 Billion | -919.77 Million | 243.76 Million |
| Net Income | -215.14 Million | -100.88 Million | -201.63 Million | -1.15 Billion | -921.55 Million | 186.81 Million |
| Earnings Per Share Basic | -0.24 | -0.11 | -0.23 | -1.31 | -1.05 | 0.21 |
| Earnings Per Share Diluted | -0.24 | -0.11 | -0.23 | -1.31 | -1.05 | 0.21 |
| Weighted Average Shares Outstanding | 879.93 Million | 879.77 Million | 879.77 Million | 879.77 Million | 879.77 Million | 879.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 879.93 Million | 879.77 Million | 879.77 Million | 879.77 Million | 879.77 Million | 879.94 Million |
| Gross Margin | 0.70 | 0.76 | 0.62 | 0.64 | 0.60 | 0.76 |
| EBIT Margin | -0.13 | 0.08 | 0.11 | -0.27 | -0.31 | 0.17 |
| Profit Margin | -0.33 | -0.12 | -0.25 | -1.32 | -0.69 | 0.07 |
| EBITDA | -83.34 Million | 22 Million | 58.1 Million | -924.82 Million | -703.12 Million | 395.78 Million |
| Earnings Before Tax Margin | -0.16 | 0.02 | -0.03 | -0.59 | -0.41 | 0.10 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 91.48 Million | 102 Million | 100.57 Million | 103.06 Million | 656.89 Million | 173.31 Million |
| Cost of Revenue | 43.03 Million | 41.22 Million | 33.84 Million | 50.16 Million | 185.51 Million | 50.72 Million |
| Gross Profit | 48.44 Million | 60.77 Million | 66.73 Million | 52.89 Million | 471.37 Million | 122.58 Million |
| Operating Expenses | 51.73 Million | 72.83 Million | 57.7 Million | 155.22 Million | 548.76 Million | 127.08 Million |
| Selling, General and Administrative Expenses | 50.75 Million | 30.28 Million | 57.3 Million | 57.63 Million | - | 165.48 Million |
| Research and Development Expenses | 3.98 Million | 2.64 Million | 1.92 Million | 38.43 Million | - | 3.89 Million |
| Other Expenses | 3.01 Million | -1.18 Million | -79.98 Thousand | 26.88 Million | 22.09 Million | -113.21 Thousand |
| Cost and Expenses | 94.76 Million | 114.05 Million | 91.54 Million | 205.39 Million | 734.28 Million | 177.8 Million |
| Operating Income | -3.28 Million | -24.74 Million | 5.13 Million | -170.71 Million | -172.91 Million | -16.78 Million |
| Interest Expense | 8 Million | 9.89 Million | 7.65 Million | 11.36 Million | 39.93 Million | 9.32 Million |
| Income Tax Expense | -325.61 Thousand | 342.71 Thousand | 53.92 Thousand | 25.62 Million | 32.83 Million | 2.88 Million |
| Earnings before Tax | -86.55 Million | -25.46 Million | 5.05 Million | -166.68 Million | -173.66 Million | -16.89 Million |
| Net Income | -82.52 Million | -27.3 Million | 3.5 Million | -179.67 Million | -215.14 Million | -22.62 Million |
| Earnings Per Share Basic | -0.09 | -0.03 | 0.00 | -0.20 | - | -0.03 |
| Earnings Per Share Diluted | -0.09 | -0.03 | 0.00 | -0.20 | - | -0.03 |
| Weighted Average Shares Outstanding | 879.77 Million | 876.32 Million | 876.32 Million | 879.6 Million | 879.93 Million | 879.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 879.77 Million | 876.32 Million | 876.32 Million | 879.6 Million | 879.93 Million | 879.77 Million |
| Gross Margin | 0.53 | 0.60 | 0.66 | 0.51 | 0.72 | 0.71 |
| EBIT Margin | -0.86 | -0.12 | 0.07 | -0.68 | - | -0.02 |
| Profit Margin | -0.90 | -0.27 | 0.03 | -1.74 | -0.33 | -0.13 |
| EBITDA | -78.55 Million | -11.82 Million | 7.11 Million | -70.55 Million | - | -3.82 Million |
| Earnings Before Tax Margin | -0.04 | -0.24 | 0.05 | -1.66 | -0.26 | -0.10 |
UTAR
272450
TCRI
OVZON
0922
VLE